The ReadoutA coming M&A boom & a close look at the drug pipeline By Damian Garde and Meghana Keshavan Jan. 9, 2017 Reprints Alex Hogan/STAT The Readout for January 09, 2017 About the Authors Reprints Damian Garde National Biotech Reporter Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast. [email protected] @damiangarde Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. [email protected] @megkesh
The Readout Meghana Keshavan Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
The Readout Damian Garde Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Business Bob Herman and Casey Ross STAT Plus: Buyer’s remorse: How a Medicare Advantage business is strangling one of its first funders
A STAT Investigation Casey Ross and Bob Herman STAT Plus: Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
Special Report Jason Mast, Allison DeAngelis and Megan Molteni STAT Plus: CRISPR patent fight redux? A new battle is brewing among biotechs over next-gen gene-editing tools
